Cath Lab
The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertension, heart failure and percutenous coronary interventions (PCI).
Abbott says the Xience fluoropolymer coating interacts with blood proteins in a manner that reduces thrombus formation. This feature makes the stent safer to use for shorter duration DAPT.
News | Stents | June 30, 2021
June 30, 2021 — Abbott announced its Xience family of drug-eluting coronary stents received U.S. Food and Drug...
The balloon inflation to deploy an Edwards Lifesciences Sapien 3 TAVR valve in a failed surgical tricuspid valve. This valve-in-valve (VIV) procedures was performed at Beaumont in a 34-year-old female patient who was determined to be too high of a surgical risk for a second surgical valve replacement.
News | Structural Heart | June 29, 2021
June 29, 2021 – Cardiologists at Beaumont Health successfully replaced a 34-year-old woman’s tricuspid valve in a rare...
News | Cardiovascular Information Systems (CVIS) | June 29, 2021
June 29, 2021 - ScImage Inc.has partnered with National Cardiovascular Management (NCM), a national consulting and...
CentraCare completed the first structural heart procedure in the world guided by a new 4-D hologram technology developed by EchoPixel. The augmented reality technology aims to reduce reduce procedure time, improve accuracy of the procedure, and reduce risk of complications.
Feature | Virtual and Augmented Reality | June 28, 2021
June 28, 2021 — CentraCare, one of the largest health systems in Minnesota, successfully completed the first structural...
Clinical trial quality data can be derived from national cardiovascular registries, which may change how trials are performed in the future. Getty Images
News | Cardiovascular Clinical Studies | June 24, 2021
June 24, 2021 — Data captured in American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR)...
The Philips Healthcare SyncVision system co-registers iFR hemodynamic blood flow measurements to live angiograms to enable easier assessment of which lesions in a vessel need to be stented and which can be left alone and treated medically.
News | FFR Technologies | June 22, 2021
June 22, 2021 – Philips Healthcare announced the official start of the DEFINE GPS study, with the first patient being...
News | Antiplatelet and Anticoagulation Therapies | June 21, 2021
June 21, 2021 — The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's dabigatran etexilate (...
Blog | Structural Heart | June 08, 2021
It is brutal and very expensive to bring a new transcatheter valve to market. Boston Scientific invested vast amounts...
Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no difference if therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI in STEMI with multi-vessel disease.
Feature | ACC | June 08, 2021 | By Dave Fornell, Editor
Here are the top 10 takeaways from the late-breaking studies on cardiovascular technologies presented at the 2021...
Two years ago a study raised concerns that paclitaxel-coated devices may cause increased mortality in peripheral artery disease patients. However, numerous studies now show there is no risk of increased mortality. The most recent study is the SAFE-PAD study presented at ACC.21.
News | Peripheral Artery Disease (PAD) | June 07, 2021
June 7, 2021 — A couple years ago a study showed a mortality safety signal in patients who underwent peripheral artery...
The 30-day outcomes from the TRISCEND study of the transfemoral Evoque tricuspid valve replacement system demonstrated technical feasibility and an acceptable safety profile, along with improvements in tricuspid regurgitation (TR) and symptoms in patients with clinically significant TR.
News | Structural Heart | June 07, 2021
June 7, 2021 — Edwards Lifesciences recently announced that clinical results from the company's transcatheter mitral...
The Aortix intra-aortic axial flow pump offers hemodynamic support to relieve some of the heart’s workload, allowing the heart to recover while more effectively pushing blood flow to the kidneys.
News | Heart Failure | June 07, 2021
June 7, 2021 – Cardiologists at Henry Ford Hospital are first in the U.S. and second in the world to implant a...
Feature | Structural Heart | June 02, 2021 | Dave Fornell, Editor
June 2, 2021 — The startup company HLT is a part of the Bracco Group, which is developing a new transcatheter aortic...
How to best anticoagulate COVID-19 patients of varying degrees of disease severity has become one of the biggest questions in medicine over the past year and there are more than 80 ongoing trials looking to answer this question. This was the top story in May 2020. Watch a VIDEO interview on this topic. Find more coronavirus-cardiology news.
Feature | June 01, 2021
June 1, 2021 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC)...
Videos | Congenital Heart | May 26, 2021
Tom Jones, M.D., director, cardiac catheterization laboratories, Seattle Children’s Hospital, explains some of the new...
